Detalhe da pesquisa
1.
Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial.
Am Heart J
; 145(1): 179-86, 2003 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-12514672